US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Medicenna Therapeutics Corp.

News headline image
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Announces Participation in Upcoming Conferences
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Announces Changes to Board Composition
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Announces Participation in Upcoming Conferences
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Announces Results of Annual Meeting of Shareholders
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA
News headline image
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
From Medicenna Therapeutics Corp.
Via GlobeNewswire
Tickers MDNAF TSX:MDNA